Pazopanib use preceding curative surgery in low rectal gastrointestinal stromal tumors after imatinib failure: A case report

Nikhil Pande; Omshree Shetty; Mounika Boppana; Anant Ramaswamy; Avanish Saklani; Nitin Shetty; Vikas Ostwal

doi:10.4103/sajc.sajc_183_18

South Asian Journal of Cancer, Table of Contents

CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(01): 51-64
DOI: 10.4103/sajc.sajc_183_18

Letter to the Editor

Pazopanib use preceding curative surgery in low rectal gastrointestinal stromal tumors after imatinib failure: A case report

Nikhil Pande

Department of Medical Oncology, TMH, Mumbai, Maharashtra

,

Omshree Shetty

Department of Pathology, TMH, Mumbai, Maharashtra

,

Mounika Boppana

Department of Medical Oncology, TMH, Mumbai, Maharashtra

,

Anant Ramaswamy

Department of Medical Oncology, TMH, Mumbai, Maharashtra

,

Avanish Saklani

Department of Surgical Oncology, TMH, Mumbai, Maharashtra

,

Nitin Shetty

Department of Interventional Radiology, TMH, Mumbai, Maharashtra

,

Vikas Ostwal

Department of Medical Oncology, TMH, Mumbai, Maharashtra

› Author Affiliations

Abstract

PDF Download

PDF (481 kb)

References

References
1 Ramaswamy A, Jain D, Sahu A, Ghosh J, Prasad P, Deodhar K, et al. Neoadjuvant imatinib: Longer the better, need to modify risk stratification for adjuvant imatinib. J Gastrointest Oncol 2016;7:624-31.
2 Zanwar S, Ostwal V, Sahu A, Jain D, Ramaswamy A, Saklani A, et al. Rectal GIST-outcomes and viewpoint from a tertiary cancer center. Indian J Gastroenterol 2016;35:445-9.
3 Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-38.
4 Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302.
5 Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol 2014;25:236-40.
6 Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): A randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016;17:632-41.
7 Ramaswamy A, Pande N, Shetty O, Shetty N, Gupta S, Ostwal V, et al. Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: Feasible and efficacious. J Gastrointest Oncol 2016;7:638-43.
8 Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, et al. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: Is it worthwhile? World J Surg Oncol 2012;10:111.
9 Svetlichnaya J, Huyck TK, Wayne JD, Agulnik M. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib. Chemotherapy 2012;58:30-3.
10 National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria for Adverse Events v4.03 (CTCAE); 2009.
11 Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31.
12 Amdahl J, Diaz J, Park J, Nakhaipour HR, Delea TE. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol 2016;23:e340-54.